Physician profile
Bruce N Benge
NPI 1558319145
$4,586.94
in general payments reported to CMS, 2019-2025
33 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $68.07 · 2021: $127 · 2022: $551 · 2023: $1,137 · 2024: $516 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439 · Education: $8.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,438.84 |
| Education | $8.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,275.07 | 2019 | |
| Emd Serono, INC. | $725.50 | 2023 | |
| Urogen Pharma, INC. | $342.45 | 2022-2025 | Jelmyto |
| Sumitomo Pharma America, INC. | $321.80 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $274.57 | 2022-2025 | |
| Astellas Pharma US INC | $267.10 | 2022-2024 | Xtandi |
| Pfizer INC. | $170.00 | 2019-2025 | |
| Janssen Biotech, INC. | $146.46 | 2021-2025 | Erleada |
| Abbvie INC. | $105.65 | 2021-2025 | Botox |
| Accord Healthcare, INC. | $90.99 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $87.68 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Myriad Genetic Laboratories, INC. | $75.38 | 2021-2024 | Prolaris |
| Tolmar, INC. | $63.65 | 2023-2025 | Eligard, Jatenzo |
| Antares Pharma, INC. | $62.60 | 2020-2024 | Xyosted, Nocdurna, Tlando |
| Ferring Pharmaceuticals INC. | $54.41 | 2024-2025 | Adstiladrin |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $47.90 | 2020-2024 | Axonics |
| Dendreon Pharmaceuticals LLC | $46.59 | 2022-2023 | Provenge |
| Myovant Sciences INC. | $44.45 | 2022 | |
| Dentsply Ih Ab | $42.88 | 2023 | Lofric |
| Progenics Pharmaceuticals, INC. | $42.01 | 2023-2025 | Pylarify |
| Ethicon US, LLC | $38.65 | 2025 | Vistaseal, Ethicon |
| E.R. Squibb & Sons, L.L.C. | $31.65 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $30.95 | 2022 | |
| Mission Pharmacal Company | $30.57 | 2022-2023 | |
| Tempus Ai, INC | $29.29 | 2025 | Xt Cdx |
| Civco Medical Instruments | $25.91 | 2025 | |
| Allergan, INC. | $24.50 | 2021 | |
| Amgen INC. | $18.76 | 2022 | |
| Verity Pharmaceuticals INC. | $15.82 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.63 | 2022 | |
| Clovis Oncology, INC. | $13.60 | 2020 | |
| Endo USA, INC. | $13.17 | 2024 | Xiaflex |
| Endo Pharmaceuticals INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Benge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.